Cover Image

OUR EXPERIENCE WITH PEMETREXED/ CISPLATIN AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON- SQUAMOUS NON- SMALL CELL LUNG CANCER

Objective: Lung cancer Pemetrexed is novel multitargeted antifolate which inhibits three key enzymes in the folate metabolic pathwaw. Methods: From May 2010 to March 2012 twenty two consecutive patients with morphologically proven advanced non- squamous non- small cell lung cancer entered the study....

Full description

Saved in:

Bibliographic Details
Main Author:	Deyan N. Davidov (Author)
Format:	Book
Published:	Peytchinski Publishing, 2013-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous non-small-cell
by: Jonathan González García, et al.
Published: (2017)

THROMBOCYTOSIS AS PROGNOSTIC FACTOR FOR SURVIVAL IN PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER TREATED WITH FIRST- LINE CHEMOTHERAPY.
by: Deyan Davidov
Published: (2014)

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
by: Serena Ricciardi, et al.
Published: (2009)

SINGLE AGENT DOCETAXEL AS SECOND- LINE CHEMOTHERAPY FOR PRETREATED PATIENTS WITH RECURRENT NON- SMALL CELL LUNG CANCER
by: Deyan N. Davidov
Published: (2013)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
by: Enriqueta Felip, et al.
Published: (2008)

OUR EXPERIENCE WITH TOPOTECAN AS SECOND- LINE TREATMENT OF PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER
by: Deyan Davidov
Published: (2010)

OUR EXPERIENCE WITH ZOLEDRONIC ACID IN THE TREATMENT OF PATIENTS WITH NON- SMALL CELL LUNG CANCER AND BONE METASTASES
by: Deyan N. Davidov
Published: (2013)

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
by: Benjamin K. Schneider, et al.
Published: (2019)

GEMCITABINE / PLATINUM VS. VINORELBINE- PLATINUM IN PATIENTS WITH ADVANCED NON- SMALL- CELL LUNG CANCER
by: Deyan Davidov
Published: (2008)

Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
by: Jing Wang, et al.
Published: (2023)

The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis
by: Zhong AY, et al.
Published: (2015)

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
by: Xueyan Liang, et al.
Published: (2023)

CAPECITABINE AND IRINOTECAN AS FIRST- LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan Davidov
Published: (2010)

Pemetrexed-induced eccrine squamous syringometaplasia manifesting as pseudocellulitis (in a patient with non-small cell lung cancer)
by: Adinia Santosa, MD, et al.
Published: (2017)

PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH FIRST - LINE CHEMOTHERAPY
by: Deyan Davidov
Published: (2017)

Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients
by: Peng Cao, et al.
Published: (2022)

Maintenance therapy with oral etoposide following first-line docetaxel-cisplatin chemotherapy in metastatic non-small cell lung cancer patients
by: Meiyu Fang, et al.
Published: (2012)

PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
by: A. U. Kulikov
Published: (2015)

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
by: Tingting Lu, et al.
Published: (2023)

The Hemoglobin Level as a Prognostic Factor in Patients with Non-Small Cell Lung Cancer Treated with Gemcitabine and cis-Platinum
by: Deyan N. Davidov
Published: (2012)

Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer
by: Qian-Yu Yang, et al.
Published: (2022)

Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer
by: S. К. Zyryanov, et al.
Published: (2024)

Validation of a novel causality assessment scale for adverse events in non-small cell lung carcinoma patients treated with platinum and pemetrexed doublet chemotherapy
by: Jyoti Bhagatram Sharma, et al.
Published: (2021)

Cost-Effectiveness Analysis of Gefitinib Alone and Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer
by: Wang Y, et al.
Published: (2022)

Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China
by: Guiyuan Xiang, et al.
Published: (2021)

Short‐Term Efficacy of Different First‐Line Chemotherapy Regimens for Advanced Non‐Small Cell Lung Cancer: A Network Meta‐Analysis
by: Bei‐Bei Zhang, et al.
Published: (2020)

First line Immunotherapy for Non-Small Cell Lung Cancer
by: Nicola J. Nasser, et al.
Published: (2020)

OUR EXPERIENCE WITH DACARBAZINE IN THE TREATMENT OF PATIENTS WITH INOPERABLE SKIN MELANOMA
by: Deyan Davidov
Published: (2016)

Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials
by: Yimeng Guo, et al.
Published: (2023)

BEVACIZUMAB COMBINED WITH IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN AS THE FIRST- LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA
by: Deyan Davidov
Published: (2014)

Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy
by: Derek B. Oien, et al.
Published: (2018)

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China
by: Liu Qiao, et al.
Published: (2021)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
by: Ranjit K Goudar
Published: (2008)

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer
by: Xuezhi Hao, et al.
Published: (2021)

Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer
by: Zhiwei Zheng, et al.
Published: (2022)

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer
by: Xia Luo, et al.
Published: (2022)

Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
by: Sharareh Seifi, et al.
Published: (2023)

Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens
by: Li LF, et al.
Published: (2024)

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review
by: Chouaïd C, et al.
Published: (2014)

Maintenance Chemotherapy With Chinese Herb Medicine Formulas vs. With Placebo in Patients With Advanced Non-small Cell Lung Cancer After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind Trial
by: Qin Wang, et al.
Published: (2018)